Most Read Articles
6 days ago
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
Yesterday
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, 2 days ago
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, 2 days ago
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.

Three-month height predicts 2-year overweight, obesity in infants small for gestational age

13 Sep 2018

In infants that are small for gestational age (SGA), stunted height at 3 months appears to predict overweight and obesity at 2 years, a recent study has found.

Researchers enrolled 468 SGA infants (mean gestational age 39.49±0.98 weeks; 248 females), in whom the mean height and weight at 3 months were 60.69±1.88 cm and 6.39±0.65 kg, respectively. As a comparison group, 4,642 appropriate for gestational age infants (mean gestational age 39.28±1.06 weeks; 2,135 females) were also enrolled.

At 2 years, 432 of the 468 SGA infants (92.3 percent) demonstrated at least –2 standard deviation scores in height and were determined to have completed height catch up. At birth, infants in the catch-up and noncatch-up groups were comparable in length (49.28±1.80 vs 48.42±2.68 cm; p=0.058), but mean birth weight was significantly lower in the latter group (2.63±0.23 vs 2.45±0.27 kg; p<0.001).

Weight at 3 months became comparable between the two groups (noncatch-up vs catch-up: 6.17±0.91 vs 6.41±0.62 kg; p=0.073), while infants in the catch-up group grew significantly taller (61.10±1.71 vs 59.31±2.84 cm; p<0.001).

After 2 years, mean body mass index was statistically similar between groups (16.20 vs 16.25 kg/m2; p=0.496), but infants in the catch-up group were significantly heavier (12.56±0.68 vs 11.37±0.96 kg; p<0.001) and taller (87.97±1.36 vs 82.88±1.39 cm; p<0.001) than those in the noncatch-up group.

Multivariate logistic regression indicated that the height at 3 months was an independent predictor for catch-up growth at 2 years (odds ratio, 1.621; 95 percent CI, 1.284–2.045; p<0.001).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
Yesterday
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, 2 days ago
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, 2 days ago
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.